- Home
- HCM vs AMLX Comparison
HCM vs AMLX Comparison
Compare HCM & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | AMLX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HCM | AMLX |
|---|---|---|
| Price | $12.64 | $35.10 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $13.75 | ★ $21.56 |
| AVG Volume (30 Days) | 40.3K | ★ 2.0M |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $15.62 | N/A |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $9.77 | $7.82 |
| 52 Week High | $17.79 | $24.60 |
Technical Indicators
Market Signals| Indicator | HCM | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.58 | 80.75 |
| Support Level | $10.73 | $12.46 |
| Resistance Level | $14.80 | N/A |
| Average True Range (ATR) | 0.27 | 1.85 |
| MACD | 0.08 | 0.66 |
| Stochastic Oscillator | 82.02 | 99.28 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.